Efficacy, safety, and pharmacokinetics (PK) of the BRAF inhibitor dabrafenib (D) hydroxypropyl methylcellulose (HPMC) capsule formulation in combination with the MEK1/2 inhibitor trametinib (T) in patients (pts) with BRAF mutation-positive metastatic melanoma (MM)

被引：0

作者：

Schuchter, Lynn Mara

Kudchadkar, Ragini Reiney

Gonzalez, Rene

Lawrence, Donald P.

Sosman, Jeffrey Alan

Infante, Jeffrey R.

Daud, Adil

Kefford, Richard

Cebon, Jonathan S.

Sharfman, William Howard

Amaravadi, Ravi K.

Boasberg, Peter D.

Lewis, Karl D.

Flaherty, Keith

Ouellet, Danielle

Little, Shonda M.

Clark, Jennifer

Gibney, Geoffrey Thomas

Patel, Kiran

Hamid, Omid

机构：

[1] Univ Penn, Philadelphia, PA 19104 USA

[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[3] UCHSC, Aurora, CO USA

[4] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[6] Sarah Cannon Res Inst, Nashville, TN USA

[7] Tennessee Oncol, Nashville, TN USA

[8] Univ Calif San Francisco, San Francisco, CA 94143 USA

[9] Westmead Hosp, Westmead, NSW 2145, Australia

[10] Melanoma Inst Australia, Westmead, NSW, Australia

[11] Austin Hlth, Melbourne, Vic, Australia

[12] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[13] Angeles Clin & Res Inst, Santa Monica, CA USA

[14] Univ Colorado, Ctr Canc, Aurora, CO USA

[15] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA

[16] GlaxoSmithKline, Res Triangle Pk, NC USA

[17] GlaxoSmithKline, Collegeville, PA USA

[18] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9066

引用

页数：1

共 37 条

[31] ROAR: a phase 2, open-label study in patients (pts) with BRAF V600E-mutated rare cancers to investigate the efficacy and safety of dabrafenib (D) and trametinib (T) combination therapy.
Subbiah, Vivek
Bang, Yung-Jue
Lassen, Ulrik Niels
Wainberg, Zev A.
Soria, Jean-Charles
Wen, Patrick Y.
Zenz, Thorsten
Moreau, Philippe
Brunsvig, Paal
Braud, Filippo G. De
De Greve, Jacques
De Jonge, Maja J.
Hofheinz, Ralf D.
Italiano, Antoine
Stein, Alexander
Willenbacher, Wolfgang
Schellens, Jan H. M.
Zielinski, Christoph
Rangwala, Fatima A.
Kreitman, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[32] Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma
Robert, C.
Karaszewska, B.
Schachter, J.
Rutkowski, P.
Mackiewicz, A.
Stroyakovskiy, D.
Lichinitser, M.
Dummer, R.
Grange, F.
Mortier, L.
Chiarion-Sileni, V.
Drucis, K.
Krajsova, I.
Hauschild, A.
Mookerjee, B.
Legos, J.
Schadendorf, D.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S663 - S664
[33] Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) plus trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma.
Flaherty, Keith
Davies, Michael A.
Grob, Jean Jacques
Long, Georgina V.
Nathan, Paul D.
Ribas, Antoni
Robert, Caroline
Schadendorf, Dirk
Frederick, Dennie T.
Hammond, Marc R.
Jane-Valbuena, Judit
Mu, Xinmeng Jasmine
Squires, Matthew
Jaeger, Savina A.
Lane, Stephen R.
Mookerjee, Bijoyesh
Garraway, Levi A.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[34] The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAFV600-mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.
Long, Georgina V.
Lebbe, Celeste
Atkinson, Victoria
Mandala, Mario
Nathan, Paul D.
Fernandez, A. N. A. Maria Arance
Richtig, Erika
Yamazaki, Naoya
Robert, Caroline
Schadendorf, Dirk
Tawbi, Hussein Abdul-Hassan
Ascierto, Paolo Antonio
Ribas, Antoni
Flaherty, Keith
Lee, Dung-Yang
Masood, Aisha
Gasal, Eduard
Dummer, Reinhard
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[35] PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K-mutant metastatic melanoma (MM) who received dabrafenib plus trametinib (D plus T) in the randomized phase 3 COMBI-v study.
Schadendorf, Dirk
Long, Georgina V.
Grob, Jean Jacques
Nathan, Paul D.
Ribas, Antoni
Davies, Michael A.
Flaherty, Keith T.
Squires, Matthew
Jaeger, Savina
Powell, William
Tan, Puay
Robert, Caroline
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[36] PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K-mutant metastatic melanoma (MM) who received dabrafenib plus trametinib (D plus T) in the randomized phase 3 COMBI-v study.
Schadendorf, Dirk
Long, Georgina V.
Grob, Jean Jacques
Nathan, Paul D.
Ribas, Antoni
Davies, Michael A.
Flaherty, Keith
Squires, Matthew
Jaeger, Savina
Powell, William
Tan, Puay
Robert, Caroline
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
[37] First-line-Therapie beim inoperablen oder metastasierten MelanomRandomisierte, offene, multizentrische Phase-I/II-Studie zur Sicherheit und Wirksamkeit einer Triple-Therapie mit dem BRAF-Inhibitor Encorafenib und dem MEK-Inhibitor Binimetinib in Kombination mit dem Anti-PD-1-Antikörper Pembrolizumab bei Patienten mit BRAF-mutiertem MelanomFirst-line therapy for inoperable or metastatic melanomaRandomized, open, multicenter phase I/II study on the safety and efficacy of triple therapy with the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib in combination with the anti-PD-1 antibody pembrolizumab in patients with BRAF-mutated melanoma
L. Zimmer
E. Livingstone
D. Schadendorf
Forum, 2020, 35 (2) : 146 - 147

← 1 2 3 4 →